Growing research over the concerns of hydroxyethyl starch (HES) as a volume expander highlighted their unsuitability in 2012 in sub-group patient populations, particularly those with severe sepsis. The findings of this research caused a stir within the pharmaceutical industry with one manufacturer of HES threatening to take legal action, claiming the findings were incorrect and misleading.
This was just the calm before the storm of evidence that would surface in 2013 supporting a ban of HES solutions.Timeline homepage
Alternatively login via
Back to epgonline.org